Clinical trials
Phase 2/3 trials in Indonesia
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
67 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 1 |
| 2007 | 1 |
| 2011 | 1 |
| 2014 | 4 |
| 2015 | 3 |
| 2016 | 3 |
| 2017 | 1 |
| 2018 | 3 |
| 2019 | 4 |
| 2020 | 13 |
| 2021 | 8 |
| 2022 | 9 |
| 2023 | 5 |
| 2024 | 4 |
| 2025 | 3 |
| 2026 | 4 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 34 |
| Unknown status | 18 |
| Terminated | 5 |
| Not yet recruiting | 4 |
| Withdrawn | 2 |
| Recruiting | 2 |
| Enrolling by invitation | 1 |
| Active, not recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Indonesia University | 10 |
| Dexa Medica Group | 7 |
| Fakultas Kedokteran Universitas Indonesia | 6 |
| PT Bio Farma | 6 |
| Duta Wacana Christian University | 4 |
| Hasanuddin University | 3 |
| Universitas Padjadjaran | 3 |
| Universitas Sriwijaya | 3 |
| National Cardiovascular Center Harapan Kita Hospital Indonesia | 2 |
| Advagene Biopharma Co. Ltd. | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| COVID-19 | 9 |
| Diabetic Neuropathies | 4 |
| Diabetes Mellitus | 3 |
| Ischemic Stroke | 2 |
| Pain | 2 |
| Tuberculosis | 2 |
| Acne Vulgaris | 1 |
| Acute Coronary Syndrome | 1 |
| Agnosia | 1 |
| Alopecia | 1 |
Trials
Showing 26 to 50 of 67. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.